| Name | Title | Contact Details |
|---|
Nexus operates 6 residential treatment sites with programming accredited by COA or TJC, and year-round, on-site schools, as well as inpatient psychiatric care programs, foster care and adoption, in-home counseling services, and ongoing support. Our programs offer a continuum of services to provide boys and girls a safe place to face their past and begin their future. We operate sites and services in Minnesota, Illinois, Maryland, North Dakota, and Idaho, each offering specialized treatment options for your child`s or adolescent`s needs. Mille Lacs Academy Gerard Academy Nexus Glen Lake Indian Oaks Academy Onarga Academy Woodbourne Center Kindred Family Focus PATH North Dakota PATH Idaho
NMotion Physical Therapy is a Jacksonville, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Gaiam, Inc. (Gaiam) is a lifestyle media company providing a selection of information, media, products and services to customers, who value personal development, wellness, ecological lifestyles, responsible media and conscious community.
Johnson Assisted Living Ctr is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sernova Corp. is a clinical-stage biotechnology company that is developing its Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells, for the treatment of chronic diseases such as insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. On implantation, the Cell Pouch forms a natural vascularized tissue environment in the body for the long-term survival and function of therapeutic cells that release essential factors absent or deficient in patients with certain chronic diseases. Sernova is also advancing a proprietary technology to shield therapeutic cells from immune system attacks with the goal to eliminate the need for chronic, systemic immunosuppression. In May 2022, the Company announced a global strategic partnership with Evotec, providing Sernova with a potentially unlimited supply of insulin-producing islet cells to treat patients with insulin-dependent diabetes (type 1 and type 2). Sernova continues to progress additional development programs utilizing its Cell Pouch System: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex-vivo lentiviral Factor VIII gene therapy for hemophilia A.